Shares in weight-loss drugmaker Eli Lilly fall on disappointing sales
US group revises down upper end of full-year revenue estimates
Read more at Financial Times
-
Eli Lilly's Zepbound and Mounjaro are no longer in shortage. Here's where their sales still disappointed
Business - CNBC - October 30 -
Chipotle misses revenue estimates as same-store sales growth disappoints
Business - CNBC - October 30 -
Lilly’s Mounjaro, Zepbound drugs see strong demand. So why did sales disappoint?
Business - MarketWatch - October 30 -
Jim Cramer identifies an interesting buy level for our worst performing Big Tech stock this year
Business - CNBC - October 31
More from Financial Times
-
Russia fires intercontinental ballistic missile at Ukraine for first time, Kyiv says
Business - Financial Times - 49 minutes ago -
Ukraine fires British Storm Shadow missiles into Russia
Business - Financial Times - 19 hours ago -
Thrive Capital: the venture firm staking billions on a few big bets
Business - Financial Times - 6 hours ago -
Bitcoin tops $98,000 in fresh high
Business - Financial Times - 6 hours ago -
Former UK deputy prime minister John Prescott dies at 86
Business - Financial Times - 4 hours ago